PipelineReview.com15h
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
HAYWARD, CA, USA I October 02, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing ...
PipelineReview.com14h
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
TEL AVIV, Israel and MADRID, Spain I October 03, 2024 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and ...
PipelineReview.com15h
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers
BASEL, Switzerland I October 02, 2024 I Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...
PipelineReview.com15h
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will ...
PipelineReview.com15h
Recordati announces agreement to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise
MILAN, Italy I October 04, 2024 I Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which ...
PipelineReview.com14h
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions ...
PipelineReview.com13h
Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
— Series B led by Goldman Sachs Alternatives with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors — — Funding will advance second-generation ...